Icovamenib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Icovamenib
- Molecular weight
- 566.67
- Structure (SMILES)
- C=CC(=O)N[C@@H]1CCCN(Cc2ccnc(C(=O)Nc3ccc(-c4cc5c(N6CCOCC6)ncnc5[nH]4)cc3)c2)C1
- bmf 219
- BMF 219 [WHO-DD]
- bmf 219 who dd
- Bmf-219
- BMF-219
- icovamenib
- Icovamenib
- icovamenib [INN]
- ICOVAMENIB [USAN]
- icovamenib 100 mg
- icovamenib 100mg
- icovamenib inn
- icovamenib usan
- CAS registry numbers
- 2448172-22-1
- ChEMBL ID
- CHEMBL6068392
- InChIKey
- CPRLHPSXWZTPMC-XMMPIXPASA-N
- PubChem compound IDs
- 154988914
- FDA ingredient codes (UNII)
- 2Z737MY35A
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- icovamenib
- Type
- Synthetic organic
- Drug name stem
- -menib
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Diabetes Mellitus, Type 1
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005147
- Subject identifier
- D003922
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Carcinoma, Pancreatic Ductal
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005184
- Subject identifier
- D021441
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition identifier
- EFO_0000222
- Condition identifier
- EFO_0000400
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005015
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005148
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018905
- Highest recorded phase
- 1
- NCT05631574
- NCT05731544
- NCT06152042
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 3
- Polar surface area
- 128.37
- Calculated partition coefficient (ALogP)
- 3.38
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 8
- Heavy atoms
- 42
- Molecular formula
- C31H34N8O3
- Monoisotopic mass
- 566.27538698
- Natural product
- No
Related records
Trials (7)
- Food Effect Study in Healthy Volunteers
- Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
- Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
- Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
- Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
- Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
- Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
In development for (9)
- Acute myeloid leukemia Phase 1
- Colorectal adenocarcinoma Phase 1
- Colorectal cancer Phase 1
- Diabetes mellitus Phase 1
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 1
- Pancreatic ductal adenocarcinoma Phase 1
- Type 1 diabetes mellitus Phase 2
- Type 2 diabetes mellitus Phase 1